Fenofibrate

Generic Name
Fenofibrate
Brand Names
Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
Drug Type
Small Molecule
Chemical Formula
C20H21ClO4
CAS Number
49562-28-9
Unique Ingredient Identifier
U202363UOS
Background

Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.

Fenofibrate was granted FDA approval on 31 December 1993.

Indication

Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.

Associated Conditions
Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
Associated Therapies
-

Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2014-12-03
Last Posted Date
2014-12-03
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
48
Registration Number
NCT02306889

Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-10-10
Last Posted Date
2018-08-24
Lead Sponsor
IlDong Pharmaceutical Co Ltd
Target Recruit Count
362
Registration Number
NCT02262143
Locations
🇰🇷

Ildong Pharm., Seoul, Korea, Republic of

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment

First Posted Date
2014-06-03
Last Posted Date
2014-06-03
Lead Sponsor
Institut Investigacio Sanitaria Pere Virgili
Target Recruit Count
30
Registration Number
NCT02153879
Locations
🇪🇸

Hospital Universitari Sant Joan, Reus, Tarragona, Spain

CKD-337 Drug Interaction Study

First Posted Date
2014-02-19
Last Posted Date
2017-08-08
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
30
Registration Number
NCT02066207
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome

First Posted Date
2013-12-19
Last Posted Date
2016-08-04
Lead Sponsor
Koval' O., MD
Target Recruit Count
60
Registration Number
NCT02015988
Locations
🇺🇦

State Institution "Dnipropetrovsk Medical Academy of Health Ministry of Ukraine", Dnipropetrovsk, Ukraine

Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-10-18
Last Posted Date
2017-06-14
Lead Sponsor
University of Miami
Target Recruit Count
6
Registration Number
NCT01965834
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Lipid Biomarkers for Diabetic Heart Disease

First Posted Date
2012-12-19
Last Posted Date
2019-03-15
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
70
Registration Number
NCT01752842
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

First Posted Date
2012-11-08
Last Posted Date
2016-09-28
Lead Sponsor
Sanofi
Target Recruit Count
79
Registration Number
NCT01723735
Locations
🇫🇷

Investigational Site Number 250001, Rennes, France

🇫🇷

Investigational Site Number 250002, Rueil Malmaison, France

Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate

First Posted Date
2012-08-16
Last Posted Date
2014-11-04
Lead Sponsor
Gachon University Gil Medical Center
Target Recruit Count
120
Registration Number
NCT01666041
Locations
🇰🇷

Gil Medical Center, Incheon, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath